Wed, May 31, 2017
Learn all the ins and outs of MACRA for 2017. Examine how physician payments will change and how you can navigate Merit-Based Incentive Payment System (MIPS) and the Alternative Payment Models. Review the timeline, tips on how to keep your practice compliant and the categories that are factored into your MACRA Quality Performance score.
After successfully completing this continuing medical education activity, participants should be able to:
- Define the possible tracks to take for MACRA 2017
- Identify who will and who won’t participate in MACRA
- Examine the criteria to qualify for APMS (Alternative Payment Models)
- Explain the timeline for MACRA’s deadlines of deliverables
- Designate the rated categories that are factored into your Quality Performance final score
- List resources available to assist you with future questions
This activity is jointly provided by Imedex®, LLC and MedMal Direct Insurance Company.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Imedex and MedMalDirect. Imedex is accredited by the ACCME to provide continuing medical education for physicians.
Imedex®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.
In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.
Disclosure of Financial Relationships
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are instructed to provide a balanced view of therapeutic options, clinically relevant and evidence-based recommendations, and avoid bias towards any specific commercial product and/or service.
All faculty participating in an Imedex activity are required to disclose relevant financial relationships that may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.
1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support
Michelle Bilsky, CHCO, LHRM, MLA, CBA
Vice President of Risk Management
MedMal Direct Insurance Company
All materials are included with the permission of the authors.
All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:
Chris Bolwell owns shares of stock of GlaxoSmithKline..
The opinions expressed in this webcast/webinar are the opinions of the presenters and do not necessarily reflect the opinions of Imedex.
MedMal Direct Disclosures
All MedMal Direct planners who are in a position to control content of this activity have no financial relationships with any commercial interests.